Covered recipient · General Payments record
RAJESH MANAM
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
General Payments · PY2018–2024
$1,402.55
- Reported across 27 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $463.39 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $166.71 | 6 |
| LUMENDI LLC | $79.00 | 1 |
| Janssen Biotech, Inc. | $66.28 | 3 |
| Celltrion USA Inc. | $53.85 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $32.55 | 1 |
| Merck Sharp & Dohme Corporation | $25.79 | 1 |
| GENZYME CORPORATION | $25.11 | 1 |
| Celgene Corporation | $14.10 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $9.55 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104951440 | CMS |
| ABBVIE INC. | $136.42 | 04/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104951444 | CMS |
| ABBVIE INC. | $6.46 | 04/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104951448 | CMS |
| ABBVIE INC. | $6.49 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104951452 | CMS |
| ABBVIE INC. | $3.12 | 11/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104951456 | CMS |
| ABBVIE INC. | $4.67 | 12/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104951459 | CMS |
| Celgene Corporation | $14.10 | 07/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101193631 | CMS |
| Celltrion USA Inc. | $22.47 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1075854819 | CMS |
| Celltrion USA Inc. | $31.38 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1075854821 | CMS |
| GENZYME CORPORATION | $25.11 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139914001 | CMS |
| Janssen Biotech, Inc. | $27.85 | 10/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078827556 | CMS |
| Janssen Biotech, Inc. | $16.40 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078827488 | CMS |
| Janssen Biotech, Inc. | $22.03 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078827642 | CMS |
| LUMENDI LLC | $79.00 | 08/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1128202922 | CMS |
| Merck Sharp & Dohme LLC | $25.79 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141707924 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $32.55 | 10/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137628535 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.